Compare Merck & Co., Inc. (MRK) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs AT&T Inc. — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while AT&T Inc. trades at $25.16 (market cap $175.42B). The key difference: Merck & Co., Inc. is far larger — about 2.1× AT&T Inc.'s market cap, and AT&T Inc. pays the higher dividend (4.34%). Which is the better fit depends on your goals.
| MRK | T | |
|---|---|---|
Market Cap | $366.28B | $175.42B |
Sector | Health | Media |
52-Week High | $156.43 | $29.62 |
52-Week Low | $77.60 | $20.49 |
Enterprise Value | $413.04B | $320.74B |
Dividend Yield | 2.29% | 4.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
AT&T (T) trades at $25.61, down slightly by 0.21% on the day. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company reported robust earnings, beating estimates in recent quarters, with a net income margin of 16.94% and attractive valuation ratios like a P/E of 8.45. Recent news highlights strategic focus on fiber and wireless growth, including a partnership with Amazon for satellite broadband.
The outlook for AT&T is positive, supported by consistent earnings beats, a solid dividend, and strategic initiatives in fiber and 5G. Key risks include high debt levels and intense competition. Analysts maintain a consensus buy rating with a $27.69 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
